Search
Plicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigationalRecurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory … [L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitIt is marketed in Canada by Valeant under the tradename Cophylac.
AGRO100
go.drugbank.com/drugs/DB04998InvestigationalAGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells.
MK-212
go.drugbank.com/drugs/DB12111InvestigationalMK-212 has been used in trials studying the treatment of Alcoholism.
Salts: MK-212 hydrochloridePeginesatide
go.drugbank.com/drugs/DB08894ApprovedWithdrawnChemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
Sulfanilamide
go.drugbank.com/drugs/DB00259ApprovedWithdrawnSulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin
Products: K. U. DOXORUBICIN HCL FOR INJECTION 50 mg/vial, K. U. DOXORUBICIN HCL FOR INJECTION 10 mg/vialProchlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.